search
CovModDrugDiscov
Trends
- 1Darrin McKenzie presents automated covalent drug discovery platform●Interesting talk by Darrin McKenzie at # CovModDrugDiscov . He talked about, how they set up an automated platform to st
Darrin McKenzie spoke at the CovModDrugDiscov conference about an automated platform his team built to study protein expression levels and cysteine engagement in living cells. The work targets covalent inhibitor drug discovery, combining chemical proteomics and chemical biology approaches. Attendees described the talk as interesting, with the automation of these assays drawing particular attention from researchers in drug discovery.
- 2Steven Gygi opens day two of covalent drug discovery meeting●The 2nd day of # CovModDrugDiscov gets on the way with an inspiring talk by Steven Gygi. He talked about the power of TM
The second day of the CovModDrugDiscov conference opened with an invited talk by Steven Gygi, a leading figure in proteomics. He presented how TMT multiplexing technologies enable high-throughput, residue-specific chemoproteomics, a method relevant to identifying targets of covalent inhibitor drugs. Attendees described the talk as inspiring, and the meeting continues to draw discussion across chemistry and chemical biology communities.
- 3AstraZeneca talk highlights computational drug discovery for KRAS G12C●Interesting talk by Michael Bodnarchuk from Astra Zeneca at # CovModDrugDiscov . He talked about the use of computationa
Michael Bodnarchuk of AstraZeneca spoke at the CovModDrugDiscov conference about using computational tools to discover covalent, brain-penetrant KRAS G12C inhibitors. The approach combines covalent chemistry with computational methods to target the KRAS G12C mutation, including drug candidates capable of crossing the blood-brain barrier. Researchers in the drug discovery and chemistry community are sharing notes on the presentation.
- 4Federica Raguseo presents phenotype-first covalent drug discovery approach●Interesting talk by Federica Raguseo at # CovModDrugDiscov . She talked about a phenotype-first approach to covalent dru
Researcher Federica Raguseo gave a talk at the CovModDrugDiscov conference on a phenotype-first approach to covalent drug discovery, using the enzyme TYMS (thymidylate synthase) as a case study. The work is associated with a recent bioRxiv preprint. Observers in the drug discovery community have highlighted the talk as an interesting example of phenotypic screening guiding the development of covalent inhibitors.